Mycobacterium genavense: Difference between revisions
Jump to navigation
Jump to search
Shanshan Cen (talk | contribs) |
m Changes made per Mahshid's request |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 12: | Line 12: | ||
| binomial_authority = Böttger et al. 1993, ATCC 51234 | | binomial_authority = Böttger et al. 1993, ATCC 51234 | ||
}} | }} | ||
{{ | {{CMG}} | ||
'''''Mycobacterium genavense'''''<br /> | '''''Mycobacterium genavense'''''<br /> | ||
| Line 48: | Line 47: | ||
===Antimicrobial regimen=== | ===Antimicrobial regimen=== | ||
* M. genavense isolates <ref>{{Cite journal| doi = 10.1164/rccm.200604-571ST| issn = 1073-449X| volume = 175| issue = 4| pages = 367–416| last1 = Griffith| first1 = David E.| last2 = Aksamit| first2 = Timothy| last3 = Brown-Elliott| first3 = Barbara A.| last4 = Catanzaro| first4 = Antonino| last5 = Daley| first5 = Charles| last6 = Gordin| first6 = Fred| last7 = Holland| first7 = Steven M.| last8 = Horsburgh| first8 = Robert| last9 = Huitt| first9 = Gwen| last10 = Iademarco| first10 = Michael F.| last11 = Iseman| first11 = Michael| last12 = Olivier| first12 = Kenneth| last13 = Ruoss| first13 = Stephen| last14 = von Reyn| first14 = C. Fordham| last15 = Wallace| first15 = Richard J.| last16 = Winthrop| first16 = Kevin| last17 = ATS Mycobacterial Diseases Subcommittee| last18 = American Thoracic Society| last19 = Infectious Disease Society of America| title = An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases| journal = American Journal of Respiratory and Critical Care Medicine| date = 2007-02-15| pmid = 17277290}}</ref> | * M. genavense isolates <ref>{{Cite journal| doi = 10.1164/rccm.200604-571ST| issn = 1073-449X| volume = 175| issue = 4| pages = 367–416| last1 = Griffith| first1 = David E.| last2 = Aksamit| first2 = Timothy| last3 = Brown-Elliott| first3 = Barbara A.| last4 = Catanzaro| first4 = Antonino| last5 = Daley| first5 = Charles| last6 = Gordin| first6 = Fred| last7 = Holland| first7 = Steven M.| last8 = Horsburgh| first8 = Robert| last9 = Huitt| first9 = Gwen| last10 = Iademarco| first10 = Michael F.| last11 = Iseman| first11 = Michael| last12 = Olivier| first12 = Kenneth| last13 = Ruoss| first13 = Stephen| last14 = von Reyn| first14 = C. Fordham| last15 = Wallace| first15 = Richard J.| last16 = Winthrop| first16 = Kevin| last17 = ATS Mycobacterial Diseases Subcommittee| last18 = American Thoracic Society| last19 = Infectious Disease Society of America| title = An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases| journal = American Journal of Respiratory and Critical Care Medicine| date = 2007-02-15| pmid = 17277290}}</ref> | ||
:* | :* Susceptibility: [[Amikacin]], [[Rifamycin]], [[Fluoroquinolones]], [[Streptomycin]], and [[Macrolides]] | ||
:* NOTE( | :* NOTE(1): [[Ethambutol]] has limited activity | ||
:* NOTE( | :* NOTE(2): Optimal therapy is not determined, but multidrug therapies including [[Clarithromycin]] appear to be more effective than those without [[Clarithromycin]] | ||
==References== | ==References== | ||
| Line 66: | Line 65: | ||
[[Category:Nontuberculous mycobacteria]] | [[Category:Nontuberculous mycobacteria]] | ||
[[Category:Gram positive bacteria]] | [[Category:Gram positive bacteria]] | ||
[[Category:Infectious Disease Project]] | [[Category:Infectious Disease Project]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 18:09, 18 September 2017
| Mycobacterium genavense | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scientific classification | ||||||||||||||
| ||||||||||||||
| Binomial name | ||||||||||||||
| Mycobacterium genavense Böttger et al. 1993, ATCC 51234 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Mycobacterium genavense
Description
A slow-growing subspecies of Mycobacterium.
Gram-positive, and nonmotile acid-fast coccobacilli (1.0µm x 2.0µm). No formation of spores, capsules or aerial hyphae.
Colony characteristics
- Tiny, transparent, nonphotochromogenic and dysgonic colonies (on solid Middlebrook 7H11 medium MJ (Allied Laboratories).
Physiology
- Slow, fastidious growth in liquid media within 3-12 weeks at 31°C, 37°C and 42°C, with slightly better growth at 45°C.
- Primary cultures for isolation require liquid broth media such as BACTEC 12B medium, Middlebrook 7H9 medium.
- Acid broth media such as,BACTEC pyrazinamidase test medium, may facilitate primary isolation.
- No growth on standard solid media like Löwenstein-Jensen, unsupplemented Middlebrook 7H11 or Middlebrook 7H10 media.
- Visible growth on solid Middlebrook 7H11 medium supplemented with MJ after inoculation with a broth culture within 3–9 weeks.
- Susceptible to streptomycin and rifampicin
- Resistant to isoniazid and ethambutol
Differential characteristics
- Differentiation from other slowly growing mycobacteria by its fastidious growth.
- Closely related to M. simiae by evaluation of 16S rDNA sequences.
Pathogenesis
- Opportunistic pathogen. Clinically indistinguishable from generalised infections in patients with AIDS due to M. avium complex strains, but more related to gastro-intestinal disorders.
- Most common cause of mycobacterial disease in parrots and parakeets.
Type Strain
Strain 2289 = ATCC 51234
Treatment
Antimicrobial regimen
- M. genavense isolates [1]
- Susceptibility: Amikacin, Rifamycin, Fluoroquinolones, Streptomycin, and Macrolides
- NOTE(1): Ethambutol has limited activity
- NOTE(2): Optimal therapy is not determined, but multidrug therapies including Clarithromycin appear to be more effective than those without Clarithromycin
References
- ↑ Griffith, David E.; Aksamit, Timothy; Brown-Elliott, Barbara A.; Catanzaro, Antonino; Daley, Charles; Gordin, Fred; Holland, Steven M.; Horsburgh, Robert; Huitt, Gwen; Iademarco, Michael F.; Iseman, Michael; Olivier, Kenneth; Ruoss, Stephen; von Reyn, C. Fordham; Wallace, Richard J.; Winthrop, Kevin; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America (2007-02-15). "An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases". American Journal of Respiratory and Critical Care Medicine. 175 (4): 367–416. doi:10.1164/rccm.200604-571ST. ISSN 1073-449X. PMID 17277290.
- Böttger et al. 1993. Mycobacterium genavense sp. nov. Int. J. Syst. Bacteriol., 43, 841-843.